Evaluating Common Prescription and Over-the-Counter Medications for Treating Adult Insomnia in a Sequential Randomized Trial

What this Trial Is About

Researchers are evaluating the effectiveness, safety, and lasting benefits of common prescription and over-the-counter medications used to treat insomnia in adults aged 18 to 80 years. The study focuses on medications including zolpidem, trazodone, melatonin, diphenhydramine, and doxepin, aiming to address the lack of clear data on which treatments offer the best balance of benefits and risks for patients with chronic insomnia. The trial responds to calls from healthcare agencies for more rigorous comparisons to guide treatment decisions in primary care. Participants will be randomly assigned to take one of these medications or a placebo nightly, 30 minutes before bed, with doses adjusted based on tolerance and response after two weeks. The study uses a double-blind, placebo-controlled design with a sequential multiple assignment approach, allowing participants who do not respond to one treatment to be re-randomized to another. All participants receive sleep hygiene education and are instructed to stay in bed for 7 to 9 hours to enhance treatment effects and safety. During the study, participants will be assessed for treatment response, side effects, and daytime symptoms over an initial one-month acute treatment phase. Those who respond will continue treatment for up to six months to evaluate longer-term benefits and safety. Assessments include sleep latency, wake after sleep onset, total sleep time, and various self-reported measures of daytime function, mood, cognition, and quality of life. The trial includes regular monitoring to track these outcomes and ensure participant safety throughout the study period.

A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia